

HemoGenyx Pharmaceuticals

17:08 14 May 2018

Hemogenyx teams up with global pharma company to help further develop CDX antibodies

HemoGenyx Pharmaceuticals PLC (LON:HEMO) has signed a deal with an unnamed global pharma company to help develop its CDX antibodies - the company's flagship treatment for blood cancer.

It is hoped these antibodies will eliminate the need for chemotherapy and radiotherapy by killing only "unwanted" cells and allowing more people who would otherwise be deemed unfit enough to receive a bone marrow transplant.

READ: Hemogenyx aims for blood cancer treatment revolution

The antibodies are currently in pre-clinical trials with a phase I study pencilled in for early next year.

Hemogenyx said Monday's deal boosts its chances of getting the antibodies into clinical trials and beyond.

Under the agreement, the global pharma company will provide Hemogenyx with free technical support, access to advanced methods of engineering antibodies as well as other things that should aid development.

In return, the pharma company will receive a research licence for anything jointly-developed under the agreement, as well as an option for an exclusive worldwide license to commercially exploit CDX antibodies or any variants, which will be jointly developed under the agreement.

Should the partner not exercise that option, Hemogenyx can license the jointly developed CDX antibodies or any variants.

WATCH: HEMO boss says progress 'surpassing expectations'

"This agreement provides additional support for our development plans for CDX antibodies, and complements the work that we are already undertaking with our own resources," said chief executive Vladislav Sandler.

"This close collaboration offers the potential for ongoing value-adding licensing arrangements with a major global pharmaceutical company with the benefit of their global reach and large-scale resources."

Hemogenyx shares soared 24% to 4.72p.

Price: 8.4

Market Cap: £36.43 m

1 Year Share Price Graph



November 2019 June 2020 November 20

Share Information

Code: HEMO

Listing: LSE

52 week High Low
15.4 0.95

Sector: Investments and investor services

Website: www.hemogenyx.com

Company Synopsis:

HemoGenyx Pharmaceuticals PLC. is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, HemoGenyx LLC, located in Brooklyn, New York at its state-of-the-art research facility ("HemoGenyx"). For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases.

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).